Get the Stockscreener App
326.31
2.95%
-9.92
After Hours:
326.57
0.26
+0.08%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Amgen Inc stock is traded at $326.31, with a volume of 3.13M.
It is down -2.95% in the last 24 hours and down -6.29% over the past month.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
See More
Previous Close:
$336.23
Open:
$336.23
24h Volume:
3.13M
Relative Volume:
1.19
Market Cap:
$176.21B
Revenue:
$37.30B
Net Income/Loss:
$7.80B
P/E Ratio:
22.69
EPS:
14.3793
Net Cash Flow:
$8.60B
1W Performance:
-1.62%
1M Performance:
-6.29%
6M Performance:
-3.10%
1Y Performance:
+20.10%
1-Day Range:
$325.16
$336.23
1-Week Range:
$325.16
$338.49
52-Week Range:
$267.73
$391.29
Amgen Inc Stock (AMGN) Company Profile
Name
Amgen Inc
Sector
Industry
Phone
(805)447-1000
Address
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN vs LLY, JNJ, ABBV, NVS, AZN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
326.31 | 181.56B | 37.30B | 7.80B | 8.60B | 14.38 |
LLY
Lilly Eli Co
|
1,004.92 | 897.72B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
226.71 | 555.59B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
210.39 | 372.39B | 62.82B | 3.60B | 19.98B | 2.0274 |
NVS
Novartis Ag Adr
|
148.08 | 285.77B | 54.66B | 13.58B | 16.05B | 7.0171 |
AZN
Astrazeneca Plc
|
181.58 | 286.84B | 60.48B | 10.40B | 8.05B | 3.3297 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-26 | Initiated | Canaccord Genuity | Hold |
| Mar-10-26 | Initiated | Jefferies | Hold |
| Feb-20-26 | Initiated | Barclays | Equal Weight |
| Jan-20-26 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-05-25 | Upgrade | Erste Group | Hold → Buy |
| Nov-24-25 | Resumed | Truist | Hold |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Sep-03-25 | Resumed | Raymond James | Mkt Perform |
| May-20-25 | Resumed | Guggenheim | Neutral |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-14-24 | Downgrade | Truist | Buy → Hold |
| Sep-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-03-24 | Upgrade | Barclays | Underweight → Equal Weight |
| May-03-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-28-24 | Resumed | Raymond James | Mkt Perform |
| Feb-07-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-21-23 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-19-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-12-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Upgrade | Truist | Hold → Buy |
| Oct-20-23 | Resumed | JP Morgan | Neutral |
| Oct-17-23 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-11-23 | Resumed | BofA Securities | Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Apr-24-23 | Reiterated | Oppenheimer | Outperform |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-13-23 | Reiterated | Truist | Buy |
| Nov-18-22 | Initiated | Credit Suisse | Underperform |
| Oct-31-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Oct-11-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-09-22 | Reiterated | Barclays | Equal Weight |
| Feb-09-22 | Reiterated | Jefferies | Buy |
| Feb-09-22 | Reiterated | Morgan Stanley | Equal-Weight |
| Feb-09-22 | Reiterated | Oppenheimer | Outperform |
| Feb-09-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Sep-23-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-29-20 | Initiated | Daiwa Securities | Buy |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-26-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-12-20 | Upgrade | Truist | Hold → Buy |
| Oct-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-09-20 | Downgrade | Truist | Buy → Hold |
| Oct-08-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-15-20 | Resumed | Guggenheim | Neutral |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Mar-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-05-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-31-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-21-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-17-19 | Resumed | Morgan Stanley | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Nov-05-19 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-19-19 | Downgrade | Mizuho | Buy → Neutral |
| May-23-19 | Upgrade | Citigroup | Neutral → Buy |
View All
Amgen Inc Stock (AMGN) Latest News
Stocks to Watch Recap: Intel, Nvidia, Amgen, LVMH -- WSJ - Moomoo
Amgen's rare disease drug linked to deaths, liver injuries in Japan, WSJ reports - Reuters
Amgen stock falls after Kissei warns on Tavneos liver risks - Investing.com
20 People in Japan Died After Taking Amgen Drug - WSJ
Amgen Inc. (AMGN) is a trending stock: Facts to know before betting on it - MSN
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Amgen Inc. $AMGN Stock Holdings Lessened by Thrivent Financial for Lutherans - MarketBeat
Conning Inc. Acquires 97,957 Shares of Amgen Inc. $AMGN - MarketBeat
Arbejdsmarkedets Tillaegspension Invests $24.26 Million in Amgen Inc. $AMGN - MarketBeat
FDA Approval for WEZLANA issued to AMGEN INC - Quantisnow
Amgen stock (US0311621009): weight-loss hopes and Prolia boost after Q1 numbers - AD HOC NEWS
Is It Time To Reassess Amgen (AMGN) After Strong Multi Year Share Price Gains - Yahoo Finance
ETFs Investing in Amgen Inc. Shs Cert Deposito Arg Repr 0.033333 Shs Stocks - TradingView
BioAge Labs, Inc. joins Amgen and Novo Nordisk to outline future obesity drug innovation at Fierce Biotech Week - Traders Union
Amgen Inc.: - marketscreener.com
Are Options Traders Betting on a Big Move in Amgen Stock? - TradingView
Oligonucleotides Clinical Trial Drug Development Pipeline Expands with Contributions from 200+ Key Companies | DelveInsight - GlobeNewswire Inc.
AMGN Maintains Overweight Rating by Piper Sandler -- Price Targe - GuruFocus
Amgen stock (US0311621009): Piper Sandler cuts price target amid rare disease review - AD HOC NEWS
Amgen stock (US0311621009): Biotech leader navigates patent cliffs and pipeline momentum - AD HOC NEWS
Piper Sandler lowers Amgen stock price target on rare disease outlook - Investing.com
Piper Sandler Maintains Amgen(AMGN.US) With Buy Rating, Cuts Target Price to $427 - Moomoo
VIRGINIA RETIREMENT SYSTEMS ET Al Has $14.47 Million Stock Holdings in Amgen Inc. $AMGN - MarketBeat
Rayburn West Financial Services LLC Acquires New Position in Amgen Inc. $AMGN - MarketBeat
Summit Wealth Group LLC Co. Has $386,000 Holdings in Amgen Inc. $AMGN - MarketBeat
Atria Investments Inc Buys 10,877 Shares of Amgen Inc. $AMGN - MarketBeat
A Look At Amgen (AMGN) Valuation After Q1 Beat Guidance Upgrade And US$300 Million US Expansion - simplywall.st
AMGN: Key products and pipeline assets drive growth, with major investments and strong Q1 results - TradingView
Amgen stock (US0311621009): Q1 earnings beat with revenue up 5.8% - AD HOC NEWS
Daiwa Securities Adjusts Price Target on Amgen to $390 From $410, Maintains Outperform Rating - marketscreener.com
Amgen stock (US0311621009): Q1 2026 earnings show net income turnaround - AD HOC NEWS
Amgen Inc. stock outperforms competitors on strong trading day - MarketWatch
Amgen stock (US0311621009): Q1 2026 earnings beat estimates with revenue up 5.8% - AD HOC NEWS
Standing Bone Strong: Introducing a New Awareness Symbol for Osteoporosis - Amgen
Scientific Approach to Obesity - Amgen
Amgen (NASDAQ:AMGN) Stock Unloaded Rep. Maria Elvira Salazar - MarketBeat
Maria Elvira Salazar trades in Amgen, Carrier Global, and Microsoft stocks - Investing.com Australia
Amgen (AMGN) VP Matthew Busch reports 41-share tax-withholding transaction - Stock Titan
Amgen (NASDAQ: AMGN) EVP uses 556 shares to cover tax obligations - Stock Titan
Amgen (NASDAQ: AMGN) HR SVP reports 151-share tax-withholding disposition - Stock Titan
Amgen (NASDAQ: AMGN) SVP reports 93-share tax-withholding disposition on Form 4 - Stock Titan
Amgen (NASDAQ: AMGN) EVP uses 499 shares for equity award tax withholding - Stock Titan
Amgen (NASDAQ: AMGN) EVP disposes 615 shares for tax withholding - Stock Titan
Amgen (NASDAQ: AMGN) CEO has 2,079 shares withheld for taxes - Stock Titan
Amgen (AMGN) EVP Bradner reports 446-share tax-withholding transaction, holds 30,016 shares - Stock Titan
Amgen Late To Raise Double-Taxation Claim, Tax Court Told - Law360
Amgen Inc. stock (US0311621009): Q1 earnings beat with $5.15 EPS - AD HOC NEWS
Amgen Inc. stock underperforms Friday when compared to competitors - MSN
AMGN Fairly Valued by DCF at $292 - GuruFocus
Amgen stock (US0311621009): Pharma giant navigates C-suite transition and Q1 growth - AD HOC NEWS
Swiss Life Asset Management Ltd Reduces Stake in Amgen Inc. $AMGN - MarketBeat
Amgen Inc Stock (AMGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):